BIOTECHNOLOGY VALUE FUND L P - 31 Dec 2024 SCHEDULE 13G/A Report for Avalo Therapeutics, Inc. Common Stock, $0.001 par value per share (AVTX)

Filing Manager
BIOTECHNOLOGY VALUE FUND L P
Reporting Manager
BVF PARTNERS L P/IL
Security
Avalo Therapeutics, Inc. Common Stock, $0.001 par value per share
Symbol
AVTX
Shares outstanding
10,395,816 shares
Disclosed Ownership
1,038,542 shares
Ownership
9.99%
Form type
SCHEDULE 13G/A
Filing time
14 Feb 2025, 16:02:30 UTC
Date of event
31 Dec 2024
Next filing
14 Nov 2025
SEC
View on sec.gov

Reporting Managers (10)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
BIOTECHNOLOGY VALUE FUND L P 5.3% 550,550 0 550,550 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF I GP LLC 5.3% 550,550 0 550,550 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BIOTECHNOLOGY VALUE FUND II LP 4.2% 432,148 0 432,148 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF II GP LLC 4.2% 432,148 0 432,148 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
Biotechnology Value Trading Fund OS LP 0.4% 40,633 0 40,633 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF Partners OS Ltd. 0.4% 40,633 0 40,633 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF GP HOLDINGS LLC 9.5% 982,698 0 982,698 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF PARTNERS L P/IL 9.99% 1,038,542 0 1,038,542 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF INC/IL 9.99% 1,038,542 0 1,038,542 /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
LAMPERT MARK N 9.99% 1,038,542 0 1,038,542 /s/ Mark N. Lampert Mark N. Lampert